Table 3.
Association between clinical characteristics, baseline GA measures, and OS among older adults with AML (N = 73)
| Baseline characteristics | Hazard ratio for mortality (95% CI) | |
|---|---|---|
| Unadjusted | Adjusted* | |
| Clinical and demographic characteristics | ||
| Age (per 10-y change) | 1.1 (0.7-1.7) | 1.3 (0.8-2.0) |
| Education (reference < high school) | ||
| High school | 0.9 (0.4-2.0) | 0.9 (0.3-2.6) |
| College | 0.8 (0.4-1.5) | 0.8 (0.3-1.8) |
| ECOG score (continuous) | 1.5 (0.9-2.4) | 1.2 (0.7-1.9) |
| Hemoglobin (continuous) | 0.8 (0.7-1.0) | 0.7 (0.6-0.9) |
| LDH (≥600) | 0.5 (0.2-1.4) | 0.6 (0.2-1.5) |
| White blood cell count (≥25 000) | 0.8 (0.4-1.6) | 1.3 (0.6-3.0) |
| Cytogenetic risk group (favorable/intermediate) | 0.5 (0.3-0.8) | 0.3 (0.2-0.7) |
| Prior MDS (not present) | 0.5 (0.3-0.8) | 0.4 (0.2-0.7) |
| GA measures | ||
| Cognitive impairment (3MS < 77) | 2.4 (1.3-4.4) | 2.5 (1.2-5.5) |
| Depressive symptoms (CES-D score ≥16) | 1.4 (0.8-2.5) | 1.0 (0.5-2.0) |
| Distress (score < 4) | 1.2 (0.6-2.1) | 1.0 (0.5-1.8) |
| IADL impairment (any at the time of treatment) | 1.3 (0.7-2.2) | 0.8 (0.4-1.6) |
| ADL impairment (any at the time of treatment) | 1.3 (0.7-2.1) | 1.1 (0.5-2.1) |
| Mobility impairment (any at the time of treatment) | 1.4 (0.7-2.6) | 1.0 (0.5-2.1) |
| Impaired physical performance (SPPB < 9) | 1.9 (1.1-3.4) | 2.2 (1.1-4.6) |
| Comorbidity burden (HCT-CI > 1) | 1.5 (0.9-2.7) | 1.2 (0.7-2.2) |
One subject with missing cytogenetic risk group data was excluded.
ADL, activities of daily living; IADL, instrumental activities of daily living; LDH, lactate dehydrogenase.
*
Adjusted model includes age, gender, ECOG performance status, cytogenetic risk group, prior MDS, and hemoglobin.